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Abstract
Background: Recommended best practice is that economic evaluation of health care interventions should be integral with
randomised clinical trials. We performed a cost-consequence analysis of treating women with mild gestational diabetes mellitus
by dietary advice, blood glucose monitoring and insulin therapy as needed compared with routine pregnancy care, using patient-
level data from a multi-centre randomised clinical trial.
Methods: Women with a singleton pregnancy who had mild gestational diabetes diagnosed by an oral glucose-tolerance test
between 24 and 34 weeks' gestation and their infants were included. Clinical outcomes and outpatient costs derived from all
women and infants in the trial. Inpatient costs derived from women and infants attending the hospital contributing the largest
number of enrolments (26.1%), and charges to women and their families derived from a subsample of participants from that
hospital (in 2002 Australian dollars). Occasions of service and health outcomes were adjusted for maternal age, ethnicity and
parity. Analysis of variance was used with bootstrapping to confirm results. Primary clinical outcomes were serious perinatal
complications; admission to neonatal nursery; jaundice requiring phototherapy; induction of labour and caesarean delivery.
Economic outcome measures were outpatient and inpatient costs, and charges to women and their families.
Results: For every 100 women with a singleton pregnancy and positive oral glucose tolerance test who were offered treatment
for mild gestational diabetes mellitus in addition to routine obstetric care, $53,985 additional direct costs were incurred at the
obstetric hospital, $6,521 additional charges were incurred by women and their families, 9.7 additional women experienced
induction of labour, and 8.6 more babies were admitted to a neonatal nursery. However, 2.2 fewer babies experienced serious
perinatal complication and 1.0 fewer babies experienced perinatal death. The incremental cost per additional serious perinatal
complication prevented was $27,503, per perinatal death prevented was $60,506 and per discounted life-year gained was $2,988.
Conclusion: It is likely that the general public in high-income countries such as Australia would find reductions in perinatal
mortality and in serious perinatal complications sufficient to justify additional health service and personal monetary charges.
Over the whole lifespan, the incremental cost per extra life-year gained is highly favourable.
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Background
Since resources are inescapably scarce, health care inter-
ventions should be assessed for their impact on costs as
well as on clinical outcomes. Recommended best practice
is that economic evaluation should be integral with ran-
domised clinical trials [1]. This has the advantage of gen-
erating patient-level data for a relatively modest research
protocol cost.
The background, methods and pregnancy outcomes of the
Australian Carbohydrate Intolerance Study in Pregnant
Women (ACHOIS) trial have been reported elsewhere [2].
Briefly, a multi-centre randomised clinical trial was con-
ducted from 1993 to 2003 to determine whether treat-
ment of women with mild gestational diabetes mellitus
reduced the risk of serious perinatal complications.
Women between 24 and 34 weeks' gestation who had
mild gestational diabetes were randomly assigned to
receive dietary advice, blood glucose monitoring, and
insulin therapy as needed (Intervention Group) or routine
care according to standard practice at each centre. (Rou-
tine-Care Group).
Eligible women had a singleton or twin pregnancy
between 16 and 30 weeks' gestation, attended antenatal
clinics at the collaborating hospitals, and after screening
positive for risk of gestational diabetes had a 75 g oral glu-
cose-tolerance (OGTT) test at 24 to 34 weeks' gestation in
which the venous plasma glucose level was less than 7.8
mmol/L after an overnight fast and 7.8 to 11.0 mmol/L at
two hours [3]. Women with more severe glucose impair-
ment were not eligible for the ACHOIS trial.
Methods
The economic evaluation took the perspective of the
health system and its patients and compared the direct
costs of the additional resources used from randomisation
until the time of postnatal hospital discharge of the
woman or her baby, whichever occurred last, with the
increments in health outcome for both the woman and
the baby in a cost-consequences analysis [4,5]. Women
with a twin pregnancy were excluded from this economic
evaluation because it was anticipated that their likely
increased use of resources could not be robustly estimated
due to their expected small numbers in the trial. This anal-
ysis included all costs, but only those primary clinical out-
comes (consequences) that achieved a P-value less than
0.05 in the main trial after adjustment for the confound-
ers of maternal age, race or ethnic group, and parity. The
economic evaluation was designed to take the form of a
cost-consequences analysis, since trading-off between the
utilities (preference values) of mother and infant would
entail difficult conceptual and ethical issues. The inten-
tion was to provide relevant information about the incre-
mental value of the intervention to assist decision-makers
in setting priorities for health resource allocation.
The costing reported in this paper began at the moment of
randomisation, and ended at the initial postnatal hospital
discharge of the woman or her baby, whichever occurred
last. Direct costs were measured to the health system and
charges to the woman and her family. Cost was calculated
as the number of occasions of each service multiplied by
its unit cost. More than 98% of participants were public
hospital patients.
Obstetric hospital outpatient occasions of service after
enrolment were collected from the trial data for all
women with a singleton pregnancy. Unit costs were
obtained from sources congruent with the Manual of
Resource Items for use in Major Submissions to the Aus-
tralian Pharmaceutical Benefits Advisory Committee
involving Economic Analyses [6]. The Manual recognises
sources that include the Schedule of Medicare Benefits [7],
the Pharmaceutical Benefits Schedule [8], and the Depart-
ment of Veterans' Affairs Schedule of Fees [9]. Unit costs
of relevant services are presented in Table 1.
Inpatient costing was only able to be performed for
women and babies who were born at the Women's and
Children's Hospital (WCH), Adelaide, Australia; the hos-
pital which recruited the largest number of women (261/
1,000; 26.1%) and which is typical of a large metropolitan
tertiary care centre in Australia. The participating clini-
cians in the ACHOIS multi-centre trial had agreed to a
common clinical management protocol. The trial began
before computerised inpatient cost information systems
became routinely available in the participating hospitals.
From 1995–96 onwards, inpatient costs were obtained
from Trendstar® (McDonnell Douglas Information Sys-
tems), the WCH patient costing system, based on input
from several feeder systems, including nursing depend-
ency levels. In this system, inpatient separations are case
mix-classified according to Australian-Refined Diagnosis
Related Groups. Cost weights come from the National
Hospital Cost Data Collection [10] and include over-
heads. Inpatient costs for the baby were added to those of
the mother.
Charges to women and their families were obtained by a
questionnaire survey of a sample of 108 South Australian
study participants (majority from the WCH) after funding
for this became available, from January 1997 to June
2003. The themes covered in the questionnaire included
time off work and costs for food, hospital parking, child-
care, and blood sugar monitoring equipment. Data from
general practitioners or community service providers were
not collected because of research budgetary constraints.
Costs were expressed in calendar year 2002 AustralianBMC Pregnancy and Childbirth 2007, 7:27 http://www.biomedcentral.com/1471-2393/7/27
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dollars, adjusted by the Consumer Price Index (CPI) [11].
Based on 2002 purchasing power parities, one Australian
dollar would convert to 0.74 US dollars, 0.48 UK pounds
or 0.66 Euros [12].
The statistical analysis of the main ACHOIS trial with a
sample size of 1000 women has been described elsewhere
[2]. A pragmatic judgment was made that the sample size
for the economic evaluation should be determined by the
limits of detection of differences in the primary outcome
measures in the main trial. The power of the study to show
differences in total health service costs was 7.5% and for
patient changes 17.5%, assuming normality. As is com-
mon in health economic evaluation, the distribution of
the costs per patient of managing gestational diabetes
mellitus was skewed; hence bootstrapping (using 10000
resamples) was used to confirm the results of the analysis
of variance [13]. All occasions of service and health out-
comes were adjusted by maternal age, race or ethnic
group, and parity.
Results
Health service use and direct outpatient costs for study 
participants
Of the 970 women in the ACHOIS trial with a singleton
pregnancy, 474 were assigned to the Intervention Group
and 496 to the Routine-Care Group. Women in the Inter-
vention Group made 0.7 fewer antenatal clinic visits (p =
0.0002), but 2.5 more specialist medical clinic visits (p <
0.0001), 1.56 more dietician visits (p < 0.0001), 1.79
more diabetes educator visits (p < 0.0001), and received
insulin therapy more often (adjusted RR 6.18, 95%CI
3.69 to 10.35, p < 0.0001) than women in the Routine-
Care Group (Table 2). Thus, across these five types of hos-
pital antenatal outpatient services, the mean direct costs
were $337 greater for women in the Intervention Group
compared with women in the Routine-Care Group (Table
3).
Primary clinical outcomes
Singleton infants in the Intervention Group were less
likely to experience any serious perinatal outcome than
infants in the Routine-Care Group (adjusted RR 0.33,
95%CI 0.14 to 0.76, p = 0.01), but were more likely to be
admitted to a neonatal nursery (adjusted RR 1.15, 95%CI
1.04 to 1.26, p = 0.004) (Table 4). Women with a single-
ton pregnancy in the Intervention Group were more likely
to have an induction of labour (adjusted RR = 1.34,
95%CI 1.13 to 1.60, p = 0.001), but were no more likely
to have a caesarean delivery (Table 4).
Inpatient costs
The inpatient costing sample consisted of 195 participat-
ing women with a singleton pregnancy from the WCH.
Compared to the remainder of the women with a single-
ton pregnancy in the ACHOIS trial, this sample was simi-
lar in maternal age and body mass index, but more likely
to be nulliparous (p = 0.01), Caucasian (p = 0.01), and to
be of lower socioeconomic status (p = 0.03). At trial entry
these women had a higher OGTT fasting result (p =
0.005), but similar two hour OGTT result (p = 0.52), and
had a five-day greater gestational age (p < 0.0001) com-
pared to the remainder of women in the trial. The mean
days of initial postnatal hospital stay for both these single-
ton women and their infants at the WCH, with adjust-
ment for year of admission, were not significantly
different from that for women in the other participating
hospitals. At the WCH, the direct costs for inpatient serv-
ices for women and infants (singleton) were $202 greater
in the Intervention Group compared with women and
infants in the Routine-Care Group, not a statistically sig-
nificant difference (p = 0.84).
Charges to participating women and their families
Of the 108 women with a singleton pregnancy providing
data from the questionnaire survey, the mean adjusted
charge from randomisation until birth, for women in the
Table 1: Unit costs of health services associated with the ambulatory management of gestational diabetes mellitus.
Item Unit cost (Australian dollars 2002) Source
Antenatal clinic visits $28.75 MBS item 16500
Physician clinic visits:
initial $119.35 MBS items 110, 116 (consultant physician)
subsequent $59.75
Dietician visits: DVA
initial $63.84 DT-03 ($5.32*12)
subsequent $31.92 DT-22 ($5.32*6)
Diabetes educator $31.92 As for dietician subsequent visit (see above)
Insulin therapy $46.26 per week Weighted average DPMQ for 11 PBS insulin 
items; Mean duration 6.4 weeks Intervention 
Group, 5.4 weeks Routine-Care Group
MBS = Medicare Benefits Schedule 1 November 2001 including 1 May 2002 Supplement; DVA = Department of Veterans' Affairs schedule of fees 
for services in a public hospital, 2002; PBS = Schedule of Pharmaceutical Benefits, November 2001; weighted by Health Insurance Commission data 
on overall population use; DPMQ = Dispensed Price for Maximum Quantity.BMC Pregnancy and Childbirth 2007, 7:27 http://www.biomedcentral.com/1471-2393/7/27
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Intervention Group and their families, was $367 com-
pared with $302 for the Routine-Care Group (p = 0.34)
(Table 5).
Costs and consequences of treatment for mild GDM
Over the course of the ACHOIS trial, for every 100 women
with a singleton pregnancy and a positive OGTT who were
offered treatment of mild gestational diabetes mellitus in
addition to standard obstetric care (Table 6),
▪ $53,985 additional direct costs were incurred at the
obstetric hospital,
▪ $6,521 additional charges were incurred by the women
and their families,
▪ 9.7 additional women experienced an induction of
labour, and
▪ 8.6 more babies were admitted to a neonatal nursery, yet
▪ 2.2 fewer babies experienced any serious perinatal com-
plication (includes perinatal death, shoulder dystocia,
bone fracture, and nerve palsy), and
▪ 1.0 fewer babies experienced a perinatal death.
Incremental cost-effectiveness ratio
Although a cost-consequences analysis was planned, the
actual trial results enabled the estimation of a credible
cost-effectiveness ratio in terms of the incremental cost for
a reduction in any serious perinatal complication. The
Table 3: Adjusted mean direct hospital outpatient costs for women with a singleton gestation
Intervention group Routine-care group
(n = 474) (n = 496)
Adjusted mean cost Adjusted mean cost Difference in adjusted mean cost
Antenatal clinic visits $125 $145 -$20
Specialist clinic visits $327 $153 $174
Dietician visits $87 $11 $76
Diabetes educator $67 $10 $57
Insulin therapy $69 $18 $51
Total $674 $337 $337
Unit costs from Table 1. Occasions of service from main ACHOIS data base.
Adjusted for maternal age, race or ethnic group, and parity.
Rounded to whole dollars
Table 2: Health services use after enrolment by women with a singleton gestation and their infants
Intervention group Routine-care group Adjusted treatment effect# (95%CI) Adjusted 
p-value
n = 474 n = 496
Antenatal services after enrolment
Antenatal inpatient admission 135 (28.5) 133(26.8) 1.11(0.91–1.36) 0.31
Antenatal clinic visits* 4.4 (1–7) 5.2(3–7) -0.70(-1.06, -0.33) 0.0002
Specialist clinic visits* 4.0 (1–7) 1.3(0–2) 2.50(2.13, 2.87) <0.0001
Dietician visits* 1.7 (1–2) 0.2(0–0) 1.56(1.39, 1.72) <0.0001
Diabetes educator visits* 2.0 (1–2) 0.2(0–0) 1.79(1.59, 1.98) <0.0001
Insulin therapy* 96 (20.3) 16 (3.2) 6.18(3.69–10.35) <0.0001
Birthing services
Induction of labour 183 (38.6) 148 (29.8) 1.34(1.13–1.60) 0.001
Caesarean birth 142(30.0) 153 (30.8) 0.97(0.80–1.17) 0.76
Neonatal services
Paediatrician present at delivery 211 (44.5) 225 (45.4) 1.02 (0.89–1.17) 0.72
Admission to neonatal nursery 330 (69.6) 294 (59.3) 1.15 (1.04–1.26) 0.004
Hours of phototherapy§ 45(24–72) 36(24–51) 0.27
Dichotomous outcomes reported as number (%) of women/babies with relative risk and 95% confidence intervals (CI) as treatment effect; 
*continuous outcomes reported as mean (interquartile range) with mean difference 95% CIs as treatment effect.
§Hours of phototherapy is median (interquartile range).
#Adjusted for maternal age, race or ethnic group and parity.BMC Pregnancy and Childbirth 2007, 7:27 http://www.biomedcentral.com/1471-2393/7/27
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incremental cost per additional serious perinatal compli-
cation prevented (defined prospectively as one or more of
the following: death, shoulder dystocia, bone fracture,
and nerve palsy) was therefore $27,503 (= ($53,985 +
$6,521)/2.2). The incremental cost per perinatal death
prevented was $60,506 (= ($53,985 + $6,521)/1.0). Based
on Australian life tables at the midpoint of the trial [14],
and a discount rate of 5%, the incremental cost per life-
year saved was $2,988 (=($53,985 + $6,521)/20.25).
Discussion
The ACHOIS trial [2] has demonstrated the clinical effec-
tiveness of active treatment of women with mild gesta-
tional diabetes and this paper reports the cost-
effectiveness of such treatment. Although a cost-conse-
quence analysis was planned, the actual trial data allowed
a credible cost-effectiveness ratio to be estimated, demon-
strating that the form of an economic analysis often can-
not be settled until data on effectiveness and cost are
actually available [15]. The ACHOIS trial also demon-
strated that the health-related quality of life of the inter-
vention mothers was better, both during the antenatal
period and three months after birth [2].
Our economic analysis used primary clinical outcome
information and use of hospital services for all 970
women with a singleton pregnancy recruited to the
ACHOIS trial. For assessing inpatient resource use, the rel-
ative differences in costs incurred by women and infants
at the hospital contributing the largest number of women
(n = 195) were assumed to be representative of those
across the whole study. This representation was used
because the trial began before computerised inpatient cost
information systems became routinely available in the
participating hospitals.
The size of this study was limited by the sample size of
1000 women in the ACHOIS trial and the small sample of
women able to be assessed for charges to families. The
power of the study to show differences was therefore low.
Even with these limitations however, these data are of
importance as there have been no previous reports of costs
Table 4: Primary clinical outcomes among women with a singleton gestation and their infants
Intervention group Routine-care group Adjusted RR (95% CI) Adjusted p-value
Infants n = 474 n = 496
Any serious perinatal complication 7 (1.5) 23 (4.6) 0.33 (0.14–0.76) 0.01
Death 0 (0.0) 5 (1.0) 0.07
Shoulder dystocia 7 (1.5) 16 (3.2) 0.46 (0.19–1.12) 0.09
Bone fracture 0 (0.0) 1 (0.2) 0.38
Nerve palsy 0 (0.0) 3 (0.6) 0.11
Admission to neonatal nursery 330 (69.6) 294 (59.3) 1.15 (1.04–1.26) 0.004
Jaundice requiring phototherapy 44 (9.3) 42 (8.5) 1.06 (0.71–1.59) 0.76
Women n = 474 n = 496
Induction of labour 183 (38.6) 148 (29.8) 1.34 (1.13–1.60) 0.001
Caesarean delivery 142 (30.0) 153 (30.8) 0.97 (0.80–1.17) 0.76
Values are number (%) of babies or women
Adjusted for maternal age, race or ethnic group, and parity
Table 5: Mean charges* to women and their family from randomisation to birth.
Intervention group (n = 52) Routine-care group (n = 56)
Adjusted mean Adjusted mean
Paid child care $24 $13
Travel (to & from appts.) $46 $42
Blood glucose monitoring equipment & consumables $53 $17
Food substitution: additional expenditure $20 $10
Subtotal $143 $82
Mother time off paid work $84 $145
Partner time off work $141 $75
Total $367 $302
* In 2002 Australian dollars, pecuniary and non-pecuniary costs. Wages calculated at the rate of Average Weekly Earnings (ABS).
Adjusted for maternal age, race or ethnic group, and parity.
Rounded to whole dollars.
Costs did not differ between groupsBMC Pregnancy and Childbirth 2007, 7:27 http://www.biomedcentral.com/1471-2393/7/27
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of treatment options for women with gestational diabetes
from randomised trials.
It is likely that the general public in high-income coun-
tries such as Australia would find the reduction in perina-
tal mortality sufficient to justify the additional costs of
$60,506, whether or not society places a larger value on a
baby's life than on that of other members of the general
public. Even incremented to current year costs, the figures
would remain highly favourable. Indeed, at a value of
$2,988, the incremental cost per life-year gained is highly
favourable. By way of comparison, George et al. [16]
found that historically the Australian Pharmaceutical Ben-
efits Advisory Committee was unlikely to recommend a
drug for government subsidy if the additional cost per life-
year gained exceeded $86,154 and was unlikely to reject a
drug for which the additional cost per life-year gained was
less than $47,612 (2002 Australian dollar values).
The results suggest that being diagnosed with mild gesta-
tional diabetes mellitus and receiving the recommended
care is not associated with any significant increase in the
direct inpatient costs or postnatal length of stay, but is
associated with an increase in the women's antenatal out-
patient costs. This includes costs due to an increase in the
number of visits to a physician, dietician and diabetes
educator. The economic evaluation has been confined to
in-trial costs and consequences. No modelling has yet
been attempted to account for either costs or conse-
quences beyond the end of the trial.
Conclusion
Treatment of women with gestational diabetes by dietary
advice, blood glucose monitoring and insulin therapy as
needed resulted in a reduction in serious perinatal com-
plications, although more women experienced an induc-
tion of labour, and more of their infants were admitted to
the neonatal nursery [2]. Treatment of women with a sin-
gleton pregnancy who have gestational diabetes in this
way resulted in increased direct costs of outpatient, obstet-
ric hospital services and direct out of pocket charges for
women and families compared with routine pregnancy
care. However, taking a perspective over the whole
lifespan, the incremental cost per extra life-year gained is
highly favourable. It is likely that the general public in
high-income countries such as Australia would find the
reductions in perinatal mortality and in serious perinatal
Table 6: Summary of direct costs post-randomisation and consequences of management of mild gestational diabetes mellitus 
expressed per 100 women with a singleton gestation
Intervention group (n = 100) Routine-care group (n = 100) Difference (n = 100)
Direct costs post-randomisation-
Antenatal ambulatory services *
Antenatal clinic $12,479 $14,483 $-2,004
Specialist clinic $32,657 $15,290 $17,367
Dietician $8,716 $1,127 $7,589
Diabetes educator $6,692 $982 $5,710
Insulin therapy $6,888 $1,800 $5,088
Subtotal $67,432 $33,681 $33,751
Inpatient services
Hospital costs† $545,125 $524,891 $20,234
Total direct health service costs $612,557 $558,572 $53,985
Patient/family costs‡ $36,749 $30,229 $6,521
Consequences§
Infants
Any serious perinatal complication¶ 1.1 3.2 -2.2
Admission to neonatal nursery 68.1 59.5 8.6
Women
Induction of labour 38.0 28.3 9.7
*Antenatal ambulatory services post-randomisation based on ACHOIS trial data for 970 women (474 in Intervention group and 496 in Routine care 
group respectively).
† Hospital costs for all mothers and babies based on WCH patient costing system (obtained from data for 195 inpatient women with a singleton 
pregnancy at the WCH).
‡ Patient/family costs obtained by survey of a patient subsample of 108 South Australian study participants.
§Based on ACHOIS trial data for 474 and 496 singleton women (respectively) (see Table 4).
¶Serious perinatal complications were defined prospectively as one or more of the following: death, shoulder dystocia, bone fracture, and nerve 
palsy.
Adjusted for maternal age, race or ethnic group, and parity.Publish with BioMed Central    and   every 
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complications sufficient to justify the additional health
service and personal monetary costs.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors contributed to the study design, interpretation
of the data and preparation of the drafts of the manu-
script. In addition CC coordinated the trial and the collec-
tion of data. KW performed the data analyses. All authors
read and approved the final manuscript.
Acknowledgements
We are indebted to the women and their children who participated in this 
study; to SJ Alton, A Deussen, I Flight, E Griffith, J Lumley, A Thomas and L 
Watson for data collection, management and monitoring; to S Brown, K 
Bruggemann and P Moore for providing the in-patient cost data; and to M 
Ewens for administrative assistance with the manuscript.
The following persons and institutions participated in the ACHOIS Trial 
Group
Blacktown District Hospital, New South Wales: D. Chipps, R. Myszka, S. Hen-
don, M. McLean, H. Merker, J. Bradford; Bradford Royal Infirmary Maternity 
Unit, United Kingdom: D. Tuffnell, J. West; Caboolture Hospital, Queensland: M. 
Ratnapala, R. Hinton, D. Woodford, D. Cave, C. Armstrong, A. Vacca, P. 
Joubert, S. Mego, V. Heazelwood; Campbelltown Hospital, Sydney, New South 
Wales: H. Grunstein, S. Fleming, B. Marney; Flinders Medical Centre, Adelaide, 
South Australia: K. Harris, J. Ebert, R. Bryce, S. Judd, M. Keirse, C. Verco; 
General Infirmary, Leeds, United Kingdom: E. Ferriman, G. Mason, C. Lidelle-
Johnson, J. Pearce; Hammersmith Hospital, London: M. de Swiet, A. McCa-
rthy;  Hervey Bay Hospital, Queensland: A. Lindberg, D. Ludwig, K. Wick-
remachandran;  Lyell McEwin Hospital, Adelaide, South Australia: G. Dekker, P. 
Duggan, I. Hocking, W. Jeffries, S. Kennedy-Andrews, N. Kretschmer, H. 
Millar, J. Mowbray; Modbury Hospital, Adelaide, South Australia: C. Archer, C. 
Hughes, G. Matthews, M. Morton, N. Price, L. Purins, N. Tamlin, J. Sieben; 
Nambour General Hospital, Queensland: C. Cocks, M. Gregora, S. Hamwood, 
G. Pinn, C. Rutherford, C. Sheehan, T. Stubbs, V. Smith-Orr; Northern Gen-
eral Hospital, Sheffield, United Kingdom: S. Rutter, C. Bruce, R. Fraser; Queen 
Elizabeth Hospital, Adelaide, South Australia: B. Pridmore (deceased), W. 
Hague, P. Phillips, M. Sladek, S. Torr; Royal North Shore Hospital, Sydney: G. 
Burton, R. Hitchman, I. Kelso, A. McElduff, J. Morris; St. George Hospital, Syd-
ney: C. Homer, G. Davis; Toowoomba Base Hospital, Queensland: P. Bridger, 
Y. Chadha, D. Gibson, M. Ratnapala; Townsville Hospital, Queensland: D. 
Watson, A. Rane, A. Robinson, J. Whitehall, S. Dunstone, R. Chadwick, A. 
Dederer, A. Lawrence; Women's and Children's Hospital, South Australia: C. 
Crowther, R. Burnet, A. McPhee, J. Robinson, A. Thomas, S. Alton, J. Hay-
ton, J. Paynter, A. Deussen, J. Avery, S. Agett, D. Morris, B. Peat, C. Wilkin-
son, V. Coppinger, J. Dodd.
References
1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL:
Methods for the economic evaluation of health care 3rd edition. Oxford
University Press; 2005. 
2. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson
JS: Effect of treatment of gestational diabetes mellitus on
pregnancy outcomes.  NEJM 2005, 2:2477-86.
3. Diabetes mellitus: report of a WHO study group.  World
Health Organ Tech Rep Ser 1985, 727:1-113.
4. Greenhalgh T: Papers that tell you what things cost (economic
analyses).  British Medical Journal 1997, 315:596-9.
5. Coast J: Is economic evaluation in touch with society's health
values?  British Medical Journal 2004, 329:1233-6.
6. Commonwealth Department of Health and Ageing: Manual of resource
items and their associated costs for use in major submissions to the Phar-
maceutical Benefits Advisory Committee involving economic analyses Can-
berra: AusInfo; 2002. 
7. Commonwealth Department of Health and Ageing: Medicare Benefits
Schedule Book Canberra: Information Services.  1 November 2001
(including 1 May 2002 update)
8. Department of Health and Ageing: Schedule of Pharmaceutical Benefits
for approved Pharmacists and Medical Practitioners Canberra: Common-
wealth Copyright Administration; 2001. 
9. Department of Veterans' Affairs for Allied Health Services
Fees   [http://www.dva.gov.au/health/provider/provider.htm]
10. Commonwealth Department of Health and Ageing: National Hospital
Cost Data Collection. Cost report round 7 (2002–2003) Canberra; 2004. 
11. Australian Bureau of Statistics: Consumer Price Index. (Cat no. 6401.0)
Canberra: ABS; 2003. 
12. Organisation for Economic Co-operation and Development
[http://www.oecd.org/std/ppp]
13. Barber JA, Thompson SG: Analysis and interpretation of cost
data in randomised controlled trials: review of published
studies.  BMJ 1998, 317(7167):1195-1200.
14. Australian Bureau of Statistics: Deaths, Australia 1999. (Cat. No.
3302.0) Canberra: ABS; 2000. 
15. Donaldson C, Hundley V, McIntosh E: Using economics alongside
clinical trials: Why we cannot choose the evaluation tech-
nique in advance.  Health Economics 1996, 5:267-269.
16. George B, Harris A, Mitchell A: Cost-effectiveness analysis and
the consistency of decision making: Evidence from pharma-
ceutical reimbursement in Australia 1991–96.  Pharmacoeco-
nomics 2001, 19:1103-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2393/7/27/prepub